We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Inexpensive Urine Test Detects Prostate Cancer

By LabMedica International staff writers
Posted on 03 Jun 2013
An inexpensive, accurate way to detect prostate cancer could facilitate commercially available, at-home or point-of-care urine tests.

The sensitive detection of cancer biomarkers in urine could revolutionize cancer diagnosis and treatment, but such detectors must be low-cost, easy to interpret, and sensitive.

Chemists at the University of California (Irvine, CA, USA) have created a way to clearly identify clinically usable markers for prostate cancer in urine, meaning that the disease could be detected far sooner, with greater accuracy and at dramatically lower cost. More...
The same technology could potentially be used for bladder and multiple myeloma cancers, which also shed identifiable markers in urine.

Salt in urine helps conduct electricity but also makes it challenging for typical biosensors to differentiate the signals of cancer molecules from the background noise around them in the electrodes. The team developed a new type of sensor by adding nanoscale protein receptors to tiny, pencil-like viruses called bacteriophages (phages) that live only within bacteria. Double wrapping the phages with additional receptors greatly increases the capture and transmission of cancer molecule signals.

The chemists constructed a bioaffinity matrix of viruses integrated into Poly(3,4-ethylenedioxythiophene) (PEDOT) films for electrochemical sensing of a prostate cancer biomarker called prostate-specific membrane antigen (PSMA). High sensitivity to PSMA resulted from synergistic action by two different ligands to PSMA on the same phage particle. One ligand was genetically encoded, and the secondary recognition ligand was chemically synthesized to wrap around the phage. The team were able to detect subnanomolar quantities of PSMA in synthetic urine solution by using the synergistic, dual-ligand phage.

Reginald M. Penner, PhD, a professor of chemistry and the study's corresponding author, said, “Our goal is a device the size of a home pregnancy test priced around USD 10. You would buy it at the drugstore or the grocery store and test yourself. We're on the verge of a very important breakthrough in a new era of personal health management. The manufacturing costs would be low, because the material costs are very, very low. The receptors for recognizing the cancer markers are really inexpensive to make. That's why we chose these viruses. The receptors are also incredibly tough. They don't need to be refrigerated and can withstand nearly boiling temperatures, meaning the portable tests could be used in myriad weather conditions and storage situations." The study was published on April 24, 2013, in the Journal of the American Chemical Society.

Related Links:

University of California



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.